Pfizer to Acquire Wyeth
January 26, 2009 - Pfizer and Wyeth announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction. The combined company will create one of the most diversified companies in the global health care industry, with product offerings in numerous growing therapeutic areas, a strong product pipeline, and leading scientific and manufacturing capabilities. To learn more about the potential of this new company, and what it means for patients, physicians, customers and investors, visit www.premierbiopharma.com.
Uninsured? Need help paying for your prescription medicine?
Pfizer has programs that may help, no matter your age or income. You may even qualify for free Pfizer medicines. Visit Pfizer Helpful Answers® to find patient assistance programs that may best meet your needs.
Join the longevity revolution.
Infoaging, an acclaimed web site from the nonprofit American Federation for Aging Research (AFAR), is dedicated to providing the knowledge we all need to live longer, healthier lives.
Information for Patients
Today, many patients want to play a more active role in their health. That's why Pfizer offers information and support to help you better understand the medicines your doctor may prescribe and the conditions these medicines treat.
Get important information about Pfizer prescription medicines.
Medicine Safety Education
Learn more about the risks and benefits of medicines-and gain a better understanding of the factors that can affect risk perception. Our interactive web hosts will guide you through a wealth of important information on medicine safety.
Licensing and Alliances
Partnering for continued innovation
We share your vision for bringing innovative products to patients around the world. Our strong commitment to collaborating with you plays a major
role in achieving this goal. That's why for more than two decades, we have worked to create successful licensing and alliance opportunities to identify, develop and commercialize products that bring value to Pfizer, our partners, and our customers.
We're interested in working with a wide range of partners throughout the world, and we welcome collaborations in all phases of scientific and technical development.
Our approach is simple: Together, we can provide genuine value for partners and patients.
Information for Health Care Providers
As your partner in providing health care solutions to patients, Pfizer brings you the information and resources you need to optimize your patient care and manage your practice.
Through PfizerPro.com, a Web site designed especially for health care providers, we offer access to product information, patient education materials, professional resources, medical information, and much more.
With our Medicine Safety Education Web site, you can access in-depth information about the science, processes, and people involved in gathering and communicating information about prescription medicines.
TOVIAZ TM (fesoterodine fumarate) is Now FDA Approved.
Pfizer's TOVIAZTM (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder.
Investor Presentations
Pfizer Investor Luncheon
Audio Webcast — Conference call for Analysts and Investors
Tuesday, January 27, 2009
12:30 PM E.S.T.
Pfizer to Acquire Wyeth
Audio Webcast — Conference call for Analysts and Investors
Monday, January 26, 2009
8:30 AM E.S.T.
Press Release — Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
Performance Report — Fourth Quarter 2008 (266 KB) PDF
Download and Print Presentation (1.04 MB) PDF
Pfizer at the 27th Annual J.P. Morgan Healthcare Conference
Audio Webcast
Tuesday, January 13, 2009
9:30 AM P.S.T.
Download and Print Presentation (4.69 MB) PDF
Pfizer Pipeline Update – Our Medicines in Development
Visit the Pfizer Pipeline to learn more about exciting breakthroughs with our medicines in development.
With the largest pipeline in the pharmaceutical industry, Pfizer and our partners are focusing on discovering and developing new medicines across 10 therapeutic areas.